INVIVYD, INC. Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value
INVIVYD, INC. (IVVD) had Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value of $0 as of 2021-12-31, per its 10-Q filed 2022-08-15.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue · last filed 2022-08-15
- 2021-12-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value $0.00.
- 2021-09-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value $0.00.
- 2020-12-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value $0.00.
| Period end | Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value |
|---|---|
| 2021-12-31 | $0.00 10-Q · filed 2022-08-15 |
| 2021-09-30 | $0.00 10-Q · filed 2021-11-15 |
| 2020-12-31 | $0.00 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |